UCB and Amgen, Inc. (NASDAQ:AMGN) have announced top-line results of the recently concluded Phase 3 study for analyzing the safety and efficacy of romosozumab in the treatment of men suffering from osteoporosis. As per the reports, the BRIDGE study data showed that it managed to meet the primary endpoint without any hassle.
The trial demonstrates a statistically significant upsurge in BMD (Bone Mineral Density) at the lumbar spine in those men who are suffering from osteoporosis, and treated with romosozumab.
The senior management team of the company is delighted to present these results. According to Sean E. Harper, EVP – R&D, Amgen, more often than not osteoporosis is perceived as a women-exclusive health issue, which isn’t true. Nowadays, it’s affecting millions of men worldwide. The data collected by research team during the study shows that romosozumab improves bone formation, which further leads to enhancement in bone mass.
Amgen took into account a handful of secondary endpoints to compare romosozumab with placebo. Reports claim that all the endpoints were met easily during the Phase 3 study. Those patients who were given romosozumab witnessed increment in their BMD at the lumbar spine, total hip and femoral neck at six months, and increase in BMD at the total hip and femoral neck at 12 months.
While sharing his words with others, UCB’s EVP & Chief Medical Officer, Dr. Iris Loew-Friedrich, said that the world has witnessed a decent progress in osteoporosis treatment lately, many unmet medical needs remain unnoticed. He further added that one in every five men and one in every three women in 50+ age group face bone injury related to osteoporosis at least once in their lifetime. The results unveiled in BRIDGE study put forth the potential of romosozumab in building bone strength to reduce fracture risk.
Going forward, UCB and Amgen will continue to work on improving their study results and add maximum value to their offerings related to osteoporosis treatment.